{"name":"Harrow Inc","slug":"harrow-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1978-01-01","label":"Natacyn first approved","drug":"Natacyn","drugSlug":"natamycin","type":"approval","sentiment":"positive"},{"date":"1986-01-01","label":"Flarex first approved","drug":"Flarex","drugSlug":"fluorometholone-acetate","type":"approval","sentiment":"positive"},{"date":"1987-01-01","label":"Iopidine first approved","drug":"Iopidine","drugSlug":"apraclonidine","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Nevanac first approved","drug":"Nevanac","drugSlug":"nepafenac","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-12-01","label":"Nevanac patent expiry (Formulation)","drug":"Nevanac","drugSlug":"nepafenac","type":"patent_expiry","sentiment":"negative"},{"date":"2032-03-31","label":"Nevanac patent expiry (Formulation)","drug":"Nevanac","drugSlug":"nepafenac","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"NEPA","genericName":"NEPA","slug":"nepa","indication":"Post-Op Ocular Inflammation","status":"marketed"},{"name":"Nevanac","genericName":"NEPAFENAC","slug":"nepafenac","indication":"Post-Op Ocular Inflammation","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Iopidine","genericName":"APRACLONIDINE","slug":"apraclonidine","indication":"Cerebrovascular Occlusion","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Flarex","genericName":"FLUOROMETHOLONE ACETATE","slug":"fluorometholone-acetate","indication":"Steroid-responsive inflammatory conditions of the eye","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Natacyn","genericName":"NATAMYCIN","slug":"natamycin","indication":"Fungal Blepharitis","status":"marketed"}]}],"pipeline":[{"name":"Iopidine","genericName":"APRACLONIDINE","slug":"apraclonidine","phase":"marketed","mechanism":"Alpha-2A adrenergic receptor","indications":["Cerebrovascular Occlusion","Increased Intraocular Pressure after Ocular Procedure","Open-angle glaucoma","Percutaneous coronary intervention","Prevention of Cerebral Thrombosis"],"catalyst":""},{"name":"NEPA","genericName":"NEPA","slug":"nepa","phase":"marketed","mechanism":"Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase","indications":["Post-Op Ocular Inflammation","Postoperative Ocular Pain"],"catalyst":""},{"name":"Flarex","genericName":"FLUOROMETHOLONE ACETATE","slug":"fluorometholone-acetate","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":["Steroid-responsive inflammatory conditions of the eye"],"catalyst":""},{"name":"Natacyn","genericName":"NATAMYCIN","slug":"natamycin","phase":"marketed","mechanism":"Small molecule","indications":["Fungal Blepharitis","Fungal conjunctivitis","Fungal keratitis"],"catalyst":""},{"name":"Nevanac","genericName":"NEPAFENAC","slug":"nepafenac","phase":"marketed","mechanism":"Nevanac works by inhibiting the enzyme prostaglandin G/H synthase 2, which is involved in producing prostaglandins that cause pain and inflammation.","indications":["Post-Op Ocular Inflammation","Postoperative Ocular Pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQdUJtOXlNQWRNRmZCWEsyWnVPdGZLR29PeVJuRU12WkRBNlBPN1FaS3ZVTnE3dHFOZEg4R2xRVG1aQWdJMklHWEZWOUhkUUxhMGhnWU5SQTRsQ3hzVHREeE1xYm5mR3VndS1JZHVzandJQ2JHRUR3WkVmcE1yNlR2NENORVhYRVJaSVZuVVZwMWtCYmZVRllhZEJTcnNucVRfYTN0bDBtQ2tfTnJUZk5RUE9hTlhUcm8tQmd0aTl1OUhpeHA2?oc=5","date":"2026-03-20","type":"pipeline","source":"AD HOC NEWS","summary":"Harrow Health Inc stock faces valuation scrutiny amid eye care expansion push - AD HOC NEWS","headline":"Harrow Health Inc stock faces valuation scrutiny amid eye care expansion push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPZFBMekJPMHNUaUZINEtqSFNfdmxLN05uX0tDcmx6U0NVRGZjQ29aY2FscVZiSTc4a0YyakV5V0xpdlpCdzB3c0xjVFE2aFpEQ1Y0ajl4TW5ETHo5MV9lUGt2WkI2a09HUHpVa0l0Si1nYlZUam1rZ054cFFvTGF0NzNzNTV2MGtGMzhYV0N0TzlGV0h3em1iRjVMTUExaHc?oc=5","date":"2026-03-17","type":"pipeline","source":"Finimize","summary":"Harrow: why this fast-growing eye-care pharma stock is worth a look - Finimize","headline":"Harrow: why this fast-growing eye-care pharma stock is worth a look","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPeEJjY2l1QTdRYlRlaGh6aHJzRXFTUXpwWFljeUFJN1JtQ0kzbWo1UE9fSW5scHByMk5ObzB6YlpweTlBanRvc2JVMGx1MGRwVTU0STNnNEw0bzM5U1RtNDEtYzVtZUJqb2FLTk5xTGlUTkF6c0ZldEtDWnQ1RzduY1hWX2dHLWoxQ1B6cmRnLUtldGhTUkxuRWh3Q1ByOWNSUUdz?oc=5","date":"2026-03-17","type":"pipeline","source":"Seeking Alpha","summary":"Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market (NASDAQ:HROW) - Seeking Alpha","headline":"Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market (NASDAQ:HROW)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQcXBnT3lSVkZva19NelpKdEV6UEdQekg4N2hNeG03ODhHSEF0T2s5NmtFRDFjT040eGRlQllOVVRmRHFqNmJtS0c1QjYyOHJsVE1qdTMwVUk1OUQ5VEJyaWdyRjlfeHRTWTBIS1RMNGI0TmYxeXZFNGl1dnJUbTFBXzFjbnF5NTjSAY8BQVVfeXFMTUNzc3BLbXNXQ1hDWWlwZkxzbk9UcEZ5MjFSOXBGbkZzcWhTbklDTGpFV0p0dWh3VXo0SmVObHl2ZVQ5NUg1SFc4Y1ZLUTRTMUtGTURZSllIY3JJZWRvM3puaEIzdlVrTjQ3WVQtZHFSUklFRjFQd1lBQkdDOC14cEVGSXYxNmpxZmUwWjdmbXc?oc=5","date":"2026-01-15","type":"pipeline","source":"Insider Monkey","summary":"Harrow, Inc. (HROW): A Bull Case Theory - Insider Monkey","headline":"Harrow, Inc. (HROW): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_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?oc=5","date":"2025-11-23","type":"pipeline","source":"msn.com","summary":"William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating - msn.com","headline":"William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPcm9Mc3B6OHI2NUZZY3BVZ1ZHd0xqOEs1dl9CclJMX3h5RGpEUER6VFIwSHpLRkx6M3VlYjg4bkpnLWRURDV1eVliTlh2Ums4WEMyOXFDZW91TTZOV3VXNm5uRHBXSW10MDUxS2xRNS1tUHU4UGFMVmQxVDNhQ2E4eUFiRjRrSHJFb0R5YWpraFpnRVJnZzdCYUZ0TWhjZkhwQkZpNkJNSjc0TllFN0R5ZTJn?oc=5","date":"2025-10-09","type":"pipeline","source":"The Capitol Forum","summary":"Harrow Shakes Up Imprimis Leadership Following Accusation from CA Board of Pharmacy - The Capitol Forum","headline":"Harrow Shakes Up Imprimis Leadership Following Accusation from CA Board of Pharmacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE8tWVBNMW9adW5YRVJoa2ZfSF9NOFdUdkJKcVJTSzJXazl4cW5SbXhlTmdGX3FPU2FPeFlEOEJMa1ctdS1Ga3JGOWdIcl9oUG1QenJSS3Y0eW84c2VrZTRNSjdWVnNBbmpfWlc4Q3N0RUJfU3o4RmJfWUJaYw?oc=5","date":"2025-10-08","type":"pipeline","source":"Yahoo Finance","summary":"Harrow, Inc. (HROW): A Bull Case Theory - Yahoo Finance","headline":"Harrow, Inc. (HROW): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-03","type":"pipeline","source":"simplywall.st","summary":"Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump - simplywall.st","headline":"Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPUWVHUGtmeW1IUWhpMndmOENIUVc1ZTdCNkwtQnJ1alZSMDR1YnFETk81LXJ1UXE3YWVNU0lJNk5GNDE5T3NneVlsTURnS25CRFl6eno4bF9FdkVpN1hzVHowNTFvRzhCNzRKa3hYbmxPdjNFbk1uZ21zSW50aGFSU21hc3Eyc2RRVmptaU9QZDBwVGFGQm1F?oc=5","date":"2025-10-01","type":"pipeline","source":"Eyes On Eyecare","summary":"Harrow to purchase Melt Pharmaceuticals - Eyes On Eyecare","headline":"Harrow to purchase Melt Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQV3J1ZG1uMXpOOUZsY2VpaGtFNWZFaHRGdTJfWW1YRFNZSWVMNlFWdEdmOUF4LTFDSjZQdmNMeDZGdUhPbm5EbThrSzRHcnM4WDlUa1ZQU3FCTkQyWll4VWR1RDhiNzVnTHZWRGx4b2VoTllxYmZmNERiblNrUlVCQncySGF4elUxeFN2YmM1NnpRNXRSejFnV2pqRmFQamhDbkVsWWdNNUVNOFNl?oc=5","date":"2025-09-26","type":"deal","source":"The Business Journals","summary":"Harrow plans to buy back former subsidiary Melt Pharmaceuticals - The Business Journals","headline":"Harrow plans to buy back former subsidiary Melt Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOYy1ya0hkQmwxcGVtcllFSkF3eUZzQlM3cmZlN0ZDS0ZFWlVfcWNGY1J5MERRWGVFbDJTQTE4ZXFQc2tFQUZIdUNmSWZHdEU3SkxOSFpwUUx5WVdIcVpFOWptWmNONmgzc1VsM2ZReW1GUnhEcEdNSXNJQUR0NlVrdVBNdEl1RVRi?oc=5","date":"2025-09-26","type":"deal","source":"Yahoo Finance","summary":"Harrow to Acquire Melt Pharmaceuticals - Yahoo Finance","headline":"Harrow to Acquire Melt Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxQd1htR1lEX1c3S0V0VW9ub3h0c1V3cDBtUEhoZktRUk1FbUkwR3dYd3dJb0VYR0dGLTBleThzNXBCYk9TV2lmdVlXMTk1eWEyOFJUeThVeG1SVlowZkJYcmEzUzlrYmxxRVZOUENMcTZPbEpZU2hIWjVsSnRtS3RnYzY5bTJGNHV1VEx3WXItWFdKcFQtdkxnNC1zT2dMRnZrQ1pIMDBnRERaRHF3a1A2Q0VmM1JocnRSUjNJTWp0b2J4YXZCel9PU0hlVmVKODhVMkZLaWNNY00ySUlYVWZOV3o5UldBSlJCM3p6Yml1LVp0eVdnMnVPT2I2QkJnVEk1Y29lU0Rpb18zNFJYMFE?oc=5","date":"2025-06-09","type":"deal","source":"prnewswire.com","summary":"Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals - prnewswire.com","headline":"Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Phar","sentiment":"neutral"}],"patents":[{"drugName":"Nevanac","drugSlug":"nepafenac","patentNumber":"9662398","type":"Formulation","expiryDate":"2030-12-01","territory":"US","genericFilings":[]},{"drugName":"Nevanac","drugSlug":"nepafenac","patentNumber":"8921337","type":"Formulation","expiryDate":"2032-03-31","territory":"US","genericFilings":[]}],"drugCount":5,"phaseCounts":{"marketed":5},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}